Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.
Stephen K TyringPhoebe RichYayoi TadaStefan BeeckIzabella MessinaJie LiuXiaohong HuangStephen ShumackPublished in: Dermatology and therapy (2023)
ClinicalTrials.gov NCT03706040.